| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| DEXCOM INC | EVP Chief Commercial Officer | Common Stock | 66.6K | $8.96M | $134.41 | Mar 12, 2024 | Direct |
| Celldex Therapeutics, Inc. | SVP & Chief Commercial Officer | ISO (right to buy) | 100K | Nov 10, 2025 | Direct | ||
| Altimmune, Inc. | Director | Stock Options (option to buy) | 48.8K | Sep 25, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| CLDX | Celldex Therapeutics, Inc. | Nov 10, 2025 | 1 | $0 | 4 | Nov 12, 2025 | SVP & Chief Commercial Officer |
| CLDX | Celldex Therapeutics, Inc. | Nov 10, 2025 | 0 | $0 | 3 | Nov 12, 2025 | SVP & Chief Commercial Officer |
| ALT | Altimmune, Inc. | Sep 25, 2025 | 1 | $0 | 4 | Sep 29, 2025 | Director |
| ALT | Altimmune, Inc. | Feb 24, 2025 | 1 | $0 | 4 | Feb 26, 2025 | Director |
| ALT | Altimmune, Inc. | Feb 24, 2025 | 0 | $0 | 3 | Feb 26, 2025 | Director |
| DXCM | DEXCOM INC | Mar 12, 2024 | 1 | -$640K | 4 | Mar 14, 2024 | EVP Chief Commercial Officer |
| DXCM | DEXCOM INC | Mar 8, 2024 | 1 | $0 | 4 | Mar 11, 2024 | EVP Chief Commercial Officer |
| DXCM | DEXCOM INC | Mar 8, 2023 | 1 | $45.40 | 4 | Mar 10, 2023 | EVP Chief Commercial Officer |
| DXCM | DEXCOM INC | Jan 9, 2023 | 0 | $0 | 3 | Jan 9, 2023 | EVP Chief Commercial Officer |